BACKGROUND: The value of serum tissue polypeptide specific antigen (TPS) as a complement to CA 19-9 in the detection of pancreatic carcinoma was determined prospectively. TPS and CA 19-9 levels obtained at the time of diagnosis in patients suspected of having chronic pancreatitis or pancreatic carcinoma were evaluated in receiver operating characteristic (ROC) curve analysis. METHODS: Serum TPS and CA 19-9 levels were measured by immunoassays in 122 subjects, 48 with pancreatic carcinoma and 74 with chronic pancreatitis. RESULTS: Elevated levels of CA 19-9 were detected preoperatively in 70% of pancreatic carcinoma patients and in 19% of chronic pancreatitis patients. Elevated levels of TPS were detected in 100% of patients with pancreatic carcinoma and in 22% of patients with chronic pancreatitis. The median levels of TPS and CA 19-9 for pancreatic carcinoma were significantly higher than those for chronic pancreatitis (P < 0.0001). Increasing the upper reference value of TPS allowed for better discrimination between chronic pancreatitis and pancreatic carcinoma. ROC curve analysis showed that the introduction of 200 U/L as a decision criterion for TPS did not reduce its sensitivity but significantly improved its specificity. At a specificity of 98% for TPS, discrimination between pancreatic carcinoma and chronic pancreatitis was found to be 97%. Increasing the upper reference level for CA 19-9 to attain a specificity of 98% decreased its sensitivity from 70% to 33%. CONCLUSIONS: At an elevated cut-off level for TPS (200 U/L), almost complete discrimination between pancreatic carcinoma and chronic pancreatitis was obtained. TPS will be more useful than CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis. Copyright 2000 American Cancer Society.
BACKGROUND: The value of serum tissue polypeptide specific antigen (TPS) as a complement to CA 19-9 in the detection of pancreatic carcinoma was determined prospectively. TPS and CA 19-9 levels obtained at the time of diagnosis in patients suspected of having chronic pancreatitis or pancreatic carcinoma were evaluated in receiver operating characteristic (ROC) curve analysis. METHODS: Serum TPS and CA 19-9 levels were measured by immunoassays in 122 subjects, 48 with pancreatic carcinoma and 74 with chronic pancreatitis. RESULTS: Elevated levels of CA 19-9 were detected preoperatively in 70% of pancreatic carcinomapatients and in 19% of chronic pancreatitispatients. Elevated levels of TPS were detected in 100% of patients with pancreatic carcinoma and in 22% of patients with chronic pancreatitis. The median levels of TPS and CA 19-9 for pancreatic carcinoma were significantly higher than those for chronic pancreatitis (P < 0.0001). Increasing the upper reference value of TPS allowed for better discrimination between chronic pancreatitis and pancreatic carcinoma. ROC curve analysis showed that the introduction of 200 U/L as a decision criterion for TPS did not reduce its sensitivity but significantly improved its specificity. At a specificity of 98% for TPS, discrimination between pancreatic carcinoma and chronic pancreatitis was found to be 97%. Increasing the upper reference level for CA 19-9 to attain a specificity of 98% decreased its sensitivity from 70% to 33%. CONCLUSIONS: At an elevated cut-off level for TPS (200 U/L), almost complete discrimination between pancreatic carcinoma and chronic pancreatitis was obtained. TPS will be more useful than CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis. Copyright 2000 American Cancer Society.
Authors: Hari Kosanam; Ioannis Prassas; Caitlin C Chrystoja; Ireena Soleas; Alison Chan; Apostolos Dimitromanolakis; Ivan M Blasutig; Felix Rückert; Robert Gruetzmann; Christian Pilarsky; Masato Maekawa; Randall Brand; Eleftherios P Diamandis Journal: Mol Cell Proteomics Date: 2013-06-24 Impact factor: 5.911
Authors: Randall E Brand; Brian M Nolen; Herbert J Zeh; Peter J Allen; Mohamad A Eloubeidi; Michael Goldberg; Eric Elton; Juan P Arnoletti; John D Christein; Selwyn M Vickers; Christopher J Langmead; Douglas P Landsittel; David C Whitcomb; William E Grizzle; Anna E Lokshin Journal: Clin Cancer Res Date: 2011-02-15 Impact factor: 12.531
Authors: Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill Journal: Curr Mol Med Date: 2013-03 Impact factor: 2.222
Authors: Jonathan M Hernandez; Sarah M Cowgill; Sam Al-Saadi; Amy Collins; Sharona B Ross; Jennifer Cooper; Desireé Villadolid; Emmanuel Zervos; Alexander Rosemurgy Journal: J Gastrointest Surg Date: 2008-10-30 Impact factor: 3.452
Authors: Jin Song; Lori J Sokoll; Jered J Pasay; Abigail L Rubin; Hanying Li; Dylan M Bach; Daniel W Chan; Zhen Zhang Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-10-17 Impact factor: 4.254